Navigation Links
Maggots Rid Patients of MRSA

University of Manchester researchers are ridding diabetic patients of the superbug MRSA - by treating their foot ulcers// with maggots.

Professor Andrew Boulton and his team used green bottle fly larvae to treat 13 diabetic patients whose foot ulcers were contaminated with MRSA and found all but one were cured within a mean period of three weeks, much quicker than the 28-week duration for the conventional treatment.

Professor Boulton, who published the results in the journal Diabetes Care, has now been awarded a £98,000 grant by Diabetes UK to carry out a randomized controlled trial to compare this treatment with two others.

"Maggots are the world's smallest surgeons. In fact they are better than surgeons - they are much cheaper and work 24 hours a day," Professor Boulton jokingly said.

"They have been used since the Napoleonic Wars and in the American Civil War they found that those who survived were the ones with maggots in their wounds: they kept them clean. They remove the dead tissue and bacteria, leaving the healthy tissue to heal.

"Still, we were very surprised to see such a good result for MRSA. There is no reason this cannot be applied to many other areas of the body, except perhaps a large abdominal wound."

Professor Boulton and his team, including senior nurse Ann Knowles, have used maggots to treat diabetic foot ulcers of patients attending the Manchester Diabetes Centre and foot clinics, as well as in in-patients at the Manchester Royal Infirmary, for ten years. More recently they found that many of their patients were suffering from MRSA-contaminated foot ulcers, with the rate doubling in a three year period, possibly due to overuse of antibiotics and the selection of broad rather than narrow-spectrum antibacterial agents. This led to their first study, funded by Central Manchester and Manchester Children's University Hospitals NHS Trust (CMMC) Chairman's Prize Award.

T hey treated 13 patients, aged 18-80 years with chronic foot ulcers that had suffered loss of feeling and reduced blood supply, with sterile free-range larvae of the green bottle fly Lucilia Sericata. They applied the larvae between two and eight times, depending on the size of the ulcer, for four days at a time, with pressure relieving dressings to protect them. No topical antimicrobial agents or growth factors were used on the study ulcer.

All but one of the patients was cleared of the superbug. During the treatment period, no adverse reactions were reported and there was a reduction in sloughy necrotic tissue and an increase in healthy, growing tissue on removal of the last larval application.

In their second study, he and his team will compare larval treatment with antibacterial silver dressings and the biogun treatment, which uses ionized air to create superoxide radicals and eradicate bacteria.

Professor Boulton said: "This is very exciting. We have demonstrated for the first time the potential of larval therapy to eliminate MRSA infection of diabetic foot ulcers. If confirmed in a randomized controlled trial, larval treatment would offer the first non-invasive and risk-free treatment of this increasing problem and a safe and cost-effective treatment in contrast to the expensive and potentially toxic antibiotic remedies."

Source-Eurekalert/B
'"/>




Related medicine news :

1. Maggots in a hospital ward!!
2. One in Three Heart Attack Patients Have No Chest Pains
3. Amphetamines Help Recovery of Stroke Patients
4. Painkillers Do Not Shorten Dying Patients Lives
5. Patients With Filariasis More Prone To HIV Infection
6. Glivec - New Hope For CMC Patients
7. Patients often assume wrongly that they are allergic to penicillin
8. New FDA Approved Drug NATRECOR For Heart Failure Patients
9. Hemochromatosis Patients Blood is Safe
10. Patients Pressure Would Result In Overprescription
11. Risk Of Decongestants In Hypertensive Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/24/2017)... ... ... Millions of families and businesses worldwide depend on high quality water from ... water. However, well water can also become contaminated with bacteria and odors from flood ... The EPA does not regulate private drinking water wells. Many states and towns do ...
(Date:9/24/2017)... ... ... boy was walking home and feeling down about himself. He didn’t think he was good ... he can do whatever he wants to do if he puts his mind to it. ... God created him with special talents and gifts. We see his internal dialogue change. He ...
(Date:9/24/2017)... ... ... The Other Sheep”: the ceremonial laws of Moses and the Holy Law of God reexamined. ... author, Maurice Caines. Maurice Caines resides in the sunny isle of Florida, but he ... Adventist Church for many years. He was previously a member of the Anglican Church ...
(Date:9/23/2017)... San Francisco, CA (PRWEB) , ... September 23, 2017 , ... ... Bay Area, is proud to announce a new blog post focused on the ARTAS® ... loss, they understandably hope to turn to the latest, most technologically sophisticated methods of ...
(Date:9/22/2017)... Albert Lea, MN (PRWEB) , ... September 22, 2017 , ... ... and video) at its rally to interview citizens on why they are rallying against ... stories and commitment to this effort against Dr. Noseworthy’s (CEO) decision to close the ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... 2017  Eli Lilly and Company (NYSE: ... data for lasmiditan, an investigational, oral, first-in-class molecule for ... improvements compared to placebo in the Phase 3 SPARTAN ... 18th Congress of the International Headache Society (IHC) in ... presented today demonstrate lasmiditan,s potential to reduce pain and ...
(Date:9/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a ... will be participating in the Morgan Stanley 15 th ... hotel in New York.  Zimmer Biomet will present on ... A live webcast of the presentation can ... http://investor.zimmerbiomet.com .   ...
(Date:9/6/2017)... Sept. 6, 2017 NeuroRx, a clinical stage biopharma ... and Behavior (ASIB), has been granted Fast Track status by ... of NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). ... trial of this sequential therapy targeting patients who are admitted ... ...
Breaking Medicine Technology: